Vaginal cuff brachytherapy: do we need to treat to more than a two-centimeter active length?

Garrett L. Jensen, MD, Parul N. Barry, MD, Harriet Eldredge-Hindy, MD, Scott R. Silva, MD, Sarah L. Todd, MD, Kendall P. Hammond, MPH, Walker R. Zimmerman, BS, Daniel S. Metzinger, MD, Moataz N. El-Ghamry, MD

Department of Radiation Oncology, Baylor Scott and White Health, Temple, USA, Department of Radiation Oncology, Division of Gynecologic Oncology, University of Louisville School of Medicine, James Graham Brown Cancer Center, Louisville, USA, Department of Radiation Oncology, UPMC Hillman Cancer Center, Magee Women’s Hospital, Pittsburgh, USA, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Louisville School of Medicine, James Graham Brown Cancer Center, Louisville, USA, Department of Biostatistics, Baylor Scott and White Health, Temple, USA

Abstract

Purpose: American Brachytherapy Society (ABS) guidelines recommend using a 3-5 cm active length (AL) when treating vaginal cuff (VC) in adjuvant setting of endometrial cancer (EC). The purpose of this study was to evaluate local control and toxicity, using an AL of 1 or 2 cm and immobilization with a traditional table-mounted (stand) or patient-mounted (suspenders) device.

Material and methods: Between 2005 and 2019, 247 patients with EC were treated with adjuvant high-dose-rate vaginal cuff (HDR-VC) brachytherapy with or without external beam radiation (EBRT). Treatment was prescribed to a 0.5 cm depth, with an AL of 1 or 2 cm, using stand or suspenders. VC boost after EBRT was typically administered with 2 fractions of 5.5 Gy, while VC brachytherapy alone was typically applied with 3 fractions of 7 Gy or 5 fractions of 5.5 Gy.

Results: The combination of suspender immobilization and an AL of 2 cm (n = 126, 51%) resulted in 5-year local control of 100%. An AL of 2 cm compared to 1 cm correlated with better local control (99.1% vs. 88.5%, p = 0.0479). Regarding immobilization, suspenders correlated with improved local control compared to stand (100% vs. 86.7%, p = 0.0038). Immobilization technique was significantly correlated with AL (p < 0.0001). Only 5 (2.0%) patients experienced grade ≥ 3 toxicity, all of whom received EBRT.

Conclusions: In the present series, an AL of 2 cm provided excellent local control, while 1 cm was inadequate. Suspenders immobilization was a practical alternative to stand immobilization in HDR brachytherapy of the vaginal cuff.

J Contemp Brachytherapy 2021;13, 3: 294-301
DOI: https://doi.org/10.5114/jcb.2021.105971

Key words: vaginal cuff, brachytherapy, immobilization, active length, endometrial.

Purpose

Endometrial cancer is the most common gynecologic malignancy in the United States, with an estimated 65,620 new cases in 2020 [1]. Many women diagnosed at an early stage have excellent survival with surgery alone. A significant risk of recurrent disease remains for women with stage I disease and high-intermediate risk features, stage II disease [2], or in more advanced stages. Vaginal cuff is the most common site of post-operative failure, and vaginal cuff brachytherapy (VCB) has become an integral part of adjuvant therapy, either with or without external beam radiotherapy (EBRT) to the pelvis, to obviate the risk of vaginal cuff recurrence in appropriately selected patients [3-7].

There is a marked lack of consensus regarding vaginal cuff treatment parameters [7-10]. This has resulted in innumerable acceptable treatment options by the American Brachytherapy Society (ABS) [11, 12]. ABS guidelines recommend treating with an active length (AL) of 3-5 cm VCB, following hysterectomy [11]. Practices vary broadly, but the most common fixed and fractional length prescriptions in endometrial cancer are 4 cm or the proximal half of the vagina, respectively [8]. Wide practice variances are often due to a lack of data. However, length of vaginal irradiation as well as volume have been known to be associated with vaginal shortening and stenosis for decades [13-16]. Less described in the literature is a relationship between the length of vagina irradiation and vaginal recurrence [14, 17]. The common prescription depth of 5 mm, though potentially more toxic than prescribing to the surface, can be justified by location of vaginal lymphatics [8, 18, 19]. Without similar evidence, and in the absence of residual disease, common VBT prescription lengths may be excessive.

Address for correspondence: Moataz N. El-Ghamry, MD, Department of Radiation Oncology, Baylor Scott and White Health, 2401 S 31st St., MS-09-C011, Temple, TX 76508, USA, phone: +1-254-724-0836, fax: +1-254-724-8061, e-mail: Moataz.ELGhamry@BSWHealth.org

Received: 21.11.2020
Accepted: 09.03.2021
Published: 07.05.2021
Vaginal cuff movement can be significant from bladder and rectum volume variation [20, 21]. The vaginal cylinder itself can also cause displacement and altered dose distribution depending on how it is positioned [22]. Traditional table-mounted immobilization (i.e., stand) of the vaginal cylinder is susceptible to inter- and intra-fraction changes in patient positioning. Custom-mounted patient immobilization devices (e.g., suspenders), may better control for these inter- and intra-fraction changes.

The aim of the present study was to evaluate the efficacy, in terms of local control and toxicity, of using a 1 or 2 cm AL in the treatment of endometrial cancer with VCB. Similarly, we evaluated the impact of immobilization technique (table- vs. patient-mounted) within the same population.

Material and methods

After obtaining institutional review board approval (IRB 017-227), 247 patients were retrospectively identified in the electronic medical record of two institutions who met all study criteria. Included patients were diagnosed with endometrial cancer and treated with adjuvant high-dose-rate (HDR) brachytherapy to the vaginal cuff, following hysterectomy with or without EBRT to the vagina and pelvis between January 2005 and November 2019. Tables 1 and 2 present patients’ and treatment’s characteristics, respectively. Patients were excluded if they had gross residual disease in the vagina or endometrial sarcoma.

Treatment of the study population was delivered via vaginal cylinder prescribed to a 0.5 cm depth, with an AL of 1 cm in 118 (47.7%) patients and 2 cm in 129 (52.2%) patients. Only 7 patients were identified who were treated with an AL of greater than 2 cm, and these patients were excluded from the analysis due to paucity of representation. Immobilization during brachytherapy was with a stand in 109 (44.1%) patients and suspenders in 138 (55.9%) patients. Suspender immobilization uses an in-house adapter attached to the vaginal cylinder central channel, with two strips of twill tape threaded into the adaptor and tied over the shoulders of the patient (Figure 1).

| Variable | Active length prescription | P-value |
|----------|---------------------------|---------|
| All, n (%) | 1 cm, n (%) | 2 cm, n (%) |
| 247 (100) | 118 (47.8) | 129 (52.2) |

| Immobilization | < 0.0001 |
|----------------|---------|
| Stand | 109 (44.1) | 106 (90.0) | 3 (2.3) |
| Suspenders | 138 (55.9) | 12 (10.2) | 126 (97.7) |

| Surgery type | < 0.0001 |
| TAH/BSO | 57 (52.3) | 16 (13.6) | 41 (31.8) |
| TAH/BSO/PLN | 49 (20.3) | 8 (6.8) | 41 (31.8) |
| TAH/BSO/PLN/PaLN | 117 (48.4) | 81 (68.6) | 36 (27.9) |
| Other | 19 (7.9) | 10 (8.5) | 9 (7.0) |

| Stage | 0.01 |
| IA | 94 (38.2) | 56 (47.5) | 38 (29.5) |
| IB | 73 (29.7) | 32 (27.1) | 41 (31.8) |
| II | 17 (6.9) | 3 (2.5) | 14 (10.9) |
| III | 58 (23.6) | 25 (21.2) | 33 (25.6) |
| IV | 4 (1.6) | 2 (1.7) | 2 (1.6) |

| Pathology | 0.0018 |
| Adenocarcinoma | 178 (72.1) | 91 (77.1) | 87 (67.4) |
| Papillary serous/clear cell | 45 (18.2) | 23 (19.5) | 22 (17.1) |
| Adenosquamous | 18 (7.3) | 4 (3.4) | 14 (10.9) |
| Other | 6 (2.4) | 0 (0.0) | 6 (4.7) |

| Grade | 0.9683 |
| 1 | 33 (14.7) | 12 (10.2) | 21 (16.3) |
| 2 | 82 (36.6) | 42 (35.6) | 40 (31.0) |
| 3 | 109 (48.6) | 48 (40.7) | 61 (47.3) |

| Follow-up time, median (range) | 36 months (3-144) | 46.5 months (3-113) | 28 months (3-144) |

TAH – total abdominal hysterectomy, BSO – bilateral salpingo-oophorectomy, PLN – pelvic lymph node dissection, PaLN – paraaortic lymph node dissection
Prior to treatment planning, fiducial markers were placed at the vaginal cuff, usually at 3 and 9 o’clock. Treatment planning was either 2D- or 3D-based, without clinical target volume (CTV) delineation. For 179 patients, 2D atlas-based library plans were used with fluoroscopy. For 68 patients, 3D planning was used with a computed tomography (CT) scan performed prior to each fraction to ensure correct placement and diameter.

**Table 2. Radiation treatment characteristics**

| Variable | 1 cm active length | 2 cm active length | P-value |
|----------|--------------------|--------------------|---------|
| Most common treatment regimens to VC only (BED$_{2}$) | 5.5 Gy × 5 ($n = 37, 35.5$ Gy$_{2}$) | 7 Gy × 3 ($n = 39, 29.8$ Gy$_{2}$) | N.A. |
| Most common boost treatment regimen with EBRT (BED$_{2}$) | 5.5 Gy × 2 following 50.4 ($n = 27$) or 45.0 Gy ($n = 22$) of EBRT (58.5–63.8 Gy$_{2}$) | 5.5 Gy × 2 following 50.4 ($n = 31$) or 45.0 Gy ($n = 12$) of EBRT (58.5–63.8 Gy$_{2}$) | N.A. |
| VC dose per fraction | 550 cGy (400–708.3) | 550 cGy (400–700) | < 0.0001 |
| VC total dose | 2050 cGy (400–4250) | 1100 cGy (550–3500) | < 0.0001 |
| VC number of fractions | 3 (1–6) | 2 (1–5) | < 0.0001 |

**EBRT**

| Yes | 57 (23.1) | 50 (20.2) | 0.0412 |
| No | 61 (24.7) | 79 (32.0) | |
| EBRT dose, median (range) | 5040 cGy (4500–5040) | 5040 cGy (4500–5625) | 0.0159 |
| Total VC BED$_{2}$, median (range) | 4899 cGy (933–7756) | 5846 cGy (992–8344) | 0.3254 |

VC – vaginal cuff, EBRT – external beam radiotherapy, BED$_{2}$ – biologic equivalent dose at 2 Gy, N.A. – not applied

**Fig. 1.** Immobilization by A) suspenders with B) custom in-house device, or with C) stand.
of the cylinder. A remote afterloader tested for channel obstruction and dwell times were independently checked. Daily QA included verification of the source position and interlocks. At the time of source exchange, after calibration, verification of the source positioning was performed. All vaginal cylinders were examined annually for physical integrity, with scans used to check for center channel damage and to verify offsets used in the treatment planning system. Cylinder diameter was chosen based on patient anatomy. Treatment plans were optimized using treatment planning software to ensure 100% isodose line coverage at 5 mm depth. On extremely rare occasions, isodose lines were manually modified to avoid the bladder or rectum.

After completion of radiation, the patients were followed every 3 months during the first 2 years and then, every 6 months up to 5 years or more. Median follow-up time was 36 months (range, 3-144 months). They were evaluated for recurrence and side effects by clinical and gynecological examinations as well as imaging studies. The patients were not censored for vaginal recurrence at the time of distant or nodal recurrence and continued to receive monitoring.

Toxicity was assessed using common terminology criteria for adverse events v. 5.0 guidelines. The highest grade of vaginal toxicity during treatment or on follow-up with a radiation oncologist or gynecologic oncologist was recorded. For all women, vaginal dilators were provided but compliance was infrequently reported and thus precluded from toxicity analysis.

Chi-square, Fisher’s exact, or Wilcoxon rank-sum tests were used to compare characteristics of the 1 and 2 cm AL populations. Bivariate analysis was used to assess overall survival by AL and vaginal recurrence as well as vaginal recurrence by AL and immobilization method. Chi-square or Fisher’s exact tests were used to test for an association between AL and toxicity. Low number of events precluded multivariate analysis. SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) was used for statistical analysis.

Results

The patients’ and treatments’ characteristics are presented in Tables 1 and 2. The patients received different fractionation schedules in terms of total dose and number of fractions, all of which were converted to a biologically effective dose (BED), at 0.5 cm depth using the L/Q model (Table 2). Those who received EBRT, typically obtained 4500 or 5040 cGy with subsequent brachytherapy to two fractions of 550 cGy (58.5-63.8 Gy\textsubscript{2} total), while patients who did not, typically received 3 fractions of 700 cGy or 5 fractions of 550 cGy (35.5 or 29.8 Gy\textsubscript{2}, respectively). Patients treated with an AL of 2 cm were significantly more likely to be immobilized with suspenders than a stand (97.7% vs. 2.3%, \(p < 0.0001\)).

For all the patients, the overall survival (OS) rates at 2 and 5 years was 95.5% and 77.0%, respectively. An OS difference was not detected by AL (\(p = 0.8050\)). Patients with a vaginal recurrence had a 5-year OS of 61.7% vs. 77.7% for those without (\(p = 0.2654\)).

For all the patients, the vaginal recurrence rates at 2 and 5 years were 1.9% and 8.0%, respectively. Overall recurrence rates at 2 and 5 years were 11.9% and 20.3%, respectively. Patients treated with an AL of 1 cm had a significantly worse 5-year vaginal recurrence free survival (VRFS) than those with an AL of 2 cm (88.5% vs. 99.1%, \(p = 0.0479\)). Patients treated with suspender immobilization had a higher 5-year VRFS (100.0% vs. 86.7%, \(p = 0.0038\)). The most common combination of 2 cm AL with suspenders (\(n = 126\), 51%) had a 100% local control at 5 years (Figure 2). Immobilization technique was significantly correlated with AL (\(p < 0.0001\)). Patients treated with or without EBRT did not have a significantly different VRFS (94.3% vs. 91.5%, \(p = 0.4354\)). Low number of events prevented log-rank analysis by EBRT and AL (Figure 3).

Table 3 shows patients’ toxicities. Grades 1-2 vaginal toxicity were experienced in 21.7% and 14.6% of patients with and without EBRT, respectively. No grade 3 or 4 vaginal toxicities were documented. Grades 1-3 rectal toxicity were experienced in 63.4% and 8.2% of patients with and without EBRT, respectively. Grades 1-3 bladder...
toxicity were experienced in 35.8% and 11.0% of patients with and without EBRT, respectively.

**Discussion**

Post-operative irradiation decreases locoregional relapses in high/intermediate-risk endometrial cancer, and vaginal cuff brachytherapy achieves vaginal control similar to EBRT with lower toxicity [3, 4]. Even though not demonstrated in randomized trials, the National Cancer Database and the Surveillance, Epidemiology, and End Results Database have shown evidence for improved survival in intermediate- and high-risk groups [23-25]. Following the PORTEC-2 demonstrating equivalent local control of vaginal cylinder to EBRT in early-stage patients with decreased toxicity [3], it makes sense to find the least toxic way to administer vaginal radiation without sacrificing local control. This is especially true without a well-established survival benefit.

In patients treated with an AL of 2 cm with suspenders, no patient developed a recurrence of the vaginal cuff. Seldom described is the effect of vaginal irradiation length on vaginal recurrence and survival. Kloetzer et al. observed no difference in survival or vaginal recurrence treating only proximal half of the vagina [17]. Surprisingly, one analysis found that overall recurrence was correlated with increased prescription length, though this was not discussed in the paper, and it was most likely due to differences in disease [14]. We found a significant difference in vaginal cuff recurrence between patients treated with an AL of 1 and 2 cm (5-year recurrence rates of 11.5% and 0.9%, respectively). There were many significant differences between the 1 and 2 cm populations, but most of those differences strengthen this finding. Patients treated with an AL of 2 cm had significantly higher stages, less extensive nodal dissections, less EBRT at lower doses, and lower total brachytherapy dose. A difference that weakens our finding was the decreased amount of...
Table 4. Vaginal recurrence in the literature

| Authors         | Year | Patients (n) | FIGO stage | EBRT (%) | Brachytherapy treatment (dose × fractions) | Depth (cm) | Median FU (months) | Vaginal recurrence (%) |
|-----------------|------|--------------|------------|----------|-------------------------------------------|------------|-------------------|-----------------------|
| Current study   | 2020 | 126          | IA-IV      | 61.2     | Median 7 Gy × 3 or 5.5 Gy × 2 (w/EBRT)   | 0.5        | 28.0              | 0.0                   |
|                 | 1    | 2020         | 118        | 48.3     | 5.5 Gy × 5 or × 2 (w/EBRT)               | 0.5        | 47.0              | 7.6                   |
| Hou et al. [26] | 2019 | 390          | stage I    | 37.2     | 5 Gy × 5-6 or 4-6 Gy × 2.3 (w/EBRT)       | 0.5        | 48.0              | 1.0                   |
| Zhang et al. [27]| 2019 | 325          | IA-IVB     | 100.0    | 4-6 Gy × 3, 5-6 Gy × 2, or 7 Gy × 1      | 0.5        | 51.0-95.0         | 1.8                   |
| Rovirosa et al. [28]| 2017 | 146          | IA-II (IR)| 0.0      | 4-6 Gy × 6, 4-5 Gy × 4, or 6 Gy × 3      | 0.5        | 41.0-88.0         | 0.0                   |
| Sorbe et al. [29]| 2012 | 527          | IA-IC (IR)| 50.0     | 3 Gy × 6, 5.9 Gy × 3, or 20 Gy (LDR)      | 0.5        | 62.0              | 3.3                   |
| Diavolitis et al. [30]| 2012 | 169          | IA         | 0.0      | 7 Gy × 3, 5.5 Gy × 4, or 70 Gy (LDR)      | 0.5 or     | 103.0             | 0.6                   |
| Nout et al.     |      |              |            |          |                                           | ovoid      |                  |                       |
| (PORTEC-2) [3]  | 2010 | 213          | IB-2A (HIR)| 0.0      | 7 Gy × 3 or 30 Gy (LDR)                   | 0.5        | 45.0              | 1.8                   |
| Alektiar et al. [31]| 2005 | 382          | IB-IIIB (IR)| 0.0     | 6-7 Gy × 3                               | 0.5        | 48.0              | 1.8                   |
| Horowitz et al. | 2002 | 164          | IB-IIIB (IR)| 0.0      | 7 Gy × 3                                 | 0.5        | 65.0              | 1.2                   |
| Peterit et al.  | 1999 | 191          | IA-C (LR-IR)| 0.0     | 16.2 Gy × 2                              | Ovoid      | 38.0              | 0.0                   |
| Eltabbahk et al. [34]| 1997 | 332          | I (LR)     | 0.0      | 30 Gy (LDR)                              | 0.5        | 97.0              | 0.0                   |
| Sorbe et al.    | 1990 | 404          | IA-IB      | 0.0      | 4.5 Gy × 6 to 9 Gy × 4                   | 1.0        | Not reported      | 0.7                   |

AL – active length of prescription, EBRT – external beam radiotherapy, FU – follow-up, IR – intermediate-risk, HR – high-risk, LDR – low-dose-rate, G – grade, 1 with suspenders, 2 with multi-channel applicators, 3 range, 4-7 Gy × 1-5, 4 range, 4-7 Gy × 1-6 follow-up time in the patients treated with an AL of 2 cm compared to 1 cm, which may have resulted in later recurrences not being captured. We were also unable to perform a multivariate analysis due to the low number of events. Table 4 demonstrates our recurrence rates in context of the literature [3, 13, 26-34]. Not all of these papers distinguished between a vaginal cuff specific recurrence and vaginal recurrence overall. In our patients, all recurrences had an epicenter within 2 cm of the vaginal apex, such that there was no difference. These papers also had varying proportions of patients who received EBRT, but receiving EBRT did not significantly impact VRFS in our study.

The length of vagina irradiation is known to be associated with vaginal shortening and stenosis [13, 35]. A recent analysis showed stenosis rates of 5% and 31%, with prescription lengths of 2.5 cm and 5.0 cm, respectively [14]. This same analysis found that stenosis rates correlated significantly with prescription depth (4% vs. 21% at the surface and 5 mm, respectively), but not with cylinder diameter, which, unlike prescription point and length, physicians tend to alter based on individual anatomy. Agnes et al. retrospectively analyzed 100 patients with endometrial cancer who received exclusive VBT post-operatively, with a median follow-up of 24 months, and found a correlation between an AL ≥ 5 cm and increased vaginal toxicity (p = 0.002) in patients who had received VBT without EBRT. In the shortest AL series published, Zhang et al. observed that vaginal shortening was > 1/3 in 9.7% of patients treated with an AL of 2.5 cm. Late grade 2 vaginal toxicity in post-operative endometrial carcinoma was associated with a 68 Gy dose equivalent to 2 Gy per fraction (α/β = 3 Gy) at 2 cm² of the vagina in patients who received EBRT and intracavitary radiation [16, 27].

Vaginal toxicity itself, particularly with regard to sexual function, is not well reported or standardized. Compliance with vaginal dilators, which in some studies has been shown to decrease vaginal atrophy [15, 36, 37], is
often not recorded, and this remained true in our retro-
spective analysis. A Cochrane review found insufficient
reliable evidence for routine vaginal dilator use, but still
recommended it in patients not sexually active [38]. Vag-
nal length changes can be reliably measured but alter-
ations in sexual function are more difficult to quantify
[39, 40]. Zhang et al. assessed late toxicity of the rectum
and bladder using Radiation Therapy Oncology Group
(RTOG) scores, while late vaginal toxicity was evaluated
with the objective criteria of LENT-SOMA [41, 42]. Here,
we assessed toxicity using CTCAE 5.0 guidelines. Since
no clear correlation of time from treatment to develop-
ment of vaginal stenosis has been found in the literature
[15, 35], we recorded the highest grade of vaginal toxicity
during the treatment or at any available follow-up with a
radiation or gynecologic oncologist. We found a high-
er rate of both bladder and vaginal toxicity (any grade)
in patients treated with an AL of 1 cm. This finding was unexpected and is most likely a result of provider and/or
institutional bias, as all 1 cm patients were treated by sev-
eral radiation oncology physicians, while a single physi-
cian treated a majority of 2 cm patients at multiple insti-
tutions. Additionally, the significantly shorter follow-up
time of 2 cm patients (28 months) may have contributed
to less late toxicity events being captured.

Unfortunately, similar institutional bias diminished
the efficacy of analysis of toxicity or recurrence by immo-
bilization type. We found a significant difference in vagi-
nal cuff recurrence by stand vs. suspender immobilization
technique (5-year recurrence rates of 13.3% and 0.0%, re-
spectively). However, there was a significant correlation
between suspender immobilization and a 2 cm AL. Only
3 patients (1.2%) were treated with a 2 cm AL using a stand,
with 1 of them having a vaginal recurrence. Interestingly,
this was the only vaginal recurrence in the patients treated
with a 2 cm AL. Due to mild toxicity in patients who did
not receive EBRT, any potential difference in side effects
using suspenders would be difficult to detect.

Suspender immobilization was clinically beneficial in
several instances. A number of patients moved during a
treatment, usually because of pain or coughing, and
thus had to be restimulated and planned. This was not
the case with suspender immobilization, as the vaginal
cylinder “moves” with the patient. At one institution, pa-
ients were typically treated in an HDR suite, following
CT simulation in the same room. When the CT scanner
was down for a repair, patients were able to receive their
simulation in a separate room and then be transported
for the treatment with the vaginal cylinder in place. Vag-
nal cylinders and stands can be marked in various ways,
but external markings cannot always accurately repli-
cate internal anatomical changes. The VC can move up
to 34.5 mm during EBRT [20]. These are largely due to
variations in the bladder and rectum volumes between
fractions, but a cylinder can also cause different displace-
ment of adjacent organs based on patient’s and stand’s
positioning [21, 22]. With suspender immobilization, the
vaginal cylinder neutrally follows and stretches patient’s
vaginal canal, which minimizes air pockets and improves
coverage at 0.5 cm depth, additionally allowing for ad-
justments that conform to motion of the vaginal canal.

Limitations of this study include its retrospective
nature and a heterogeneous cohort, with regard to stage,
dose, follow-up time, and surgery. Most signifi-
cantly, patients treated with an AL of 2 cm had a sig-
nificantly shorter follow-up time. There was a limited
number of patients treated with an AL of 2 cm with a
stand immobilization or an AL of 1 cm with suspender
immobilization.

Conclusions

Excellent control of the vaginal cuff was obtained
using patient-mounted suspender immobilization while
treating to an AL of 2 cm. Treating to an AL of 1 cm cor-
related with a significantly increased frequency of the
vaginal cuff recurrence. The suspender immobilization
offers several practical advantages and is a viable alterna-
tive to the stand immobilization in HDR brachytherapy
of the vaginal cuff. Optimal brachytherapy with regards
to dose, fractionation, and other treatment parameters
remains ill-defined. More research, preferably with ran-
domized phase III trials incorporating more objective and
detailed monitoring of vaginal toxicity are needed.

Disclosure

Dr. Barry received an ACRO grant for a survey evalu-
ing promotion of women in radiation oncology. Other-
wise, none to disclose.

The authors report no conflict of interest.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA
Cancer J Clin 2020; 70: 7-30.
2. Rychlik A, Zapardiel I, Baquedano L et al. Clinical relevance
of high–intermediate risk endometrial cancer according to
European risk classification. Int J Gynecol Cancer 2020; 30:
1528-1534.
3. Nout R, Smit V, Putter H et al. Vaginal brachytherapy ver-
sus pelvic external beam radiotherapy for patients with en-
dometrial cancer of high–intermediate risk (PORTEC-2): an
open-label, non-inferiority, randomised trial. Lancet 2010;
375: 816-823.
4. Creutzberg CL, Nout RA, Lybeert MLM et al. Fifteen-year ra-
diotherapy outcomes of the randomized PORTEC-1 trial for
endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011;
81: e631-e638.
5. Nout RA, Putter H, Jürgenliemk-Schulz IM et al. Five-year
quality of life of endometrial cancer patients treated in the
randomised Post Operative Radiation Therapy in Endome-
trial Cancer (PORTEC)-2 trial and comparison with norm
data. Eur J Cancer 2012; 48: 1638-1648.
6. Keys HM, Roberts JA, Brunetto VL et al. A phase III trial of
surgery with or without adjunctive external pelvic radiation
therapy in intermediate risk endometrial adenocarcinoma:
a Gynaecologic Oncology Group study. Gynecol Oncol
2004; 92: 744-751.
7. Harkenrider MM, Block AM, Alektiar KM et al. American
Brachytherapy Task Group Report: Adjuvant vaginal
brachytherapy for early-stage endometrial cancer: A com-
prehensive review. Brachytherapy 2017; 16: 95-108.
8. Harkenrider MM, Grover S, Erickson BA et al. Vaginal
brachytherapy for postoperative endometrial cancer: 2014
Survey of the American Brachytherapy Society. Brachyther-
apy 2016; 15: 23-29.
9. Harkenrider MM, Block AM, Siddiqui ZA, Small W Jr. The role of vaginal cuff brachytherapy in endometrial cancer. *Gynecol Oncol* 2015; 136: 365-372.

10. Albuquerque K, Hrycushko BA, Harkenrider MM et al. Compendium of fractionation choices for gynecologic HDR brachytherapy – an American Brachytherapy Society Task Group Report. *Brachytherapy* 2019; 18: 429-436.

11. Small W Jr., Berival S, Demanes DJ et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. *Brachytherapy* 2012; 11: 58-67.

12. Nag S, Erickson B, Thomadsen B et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. *Int J Radiat Oncol Biol Phys* 2000; 48: 201-211.

13. Sorbe BG, Smeds AC. Postoperative vaginal irradiation with high dose rate afterloading technique in endometrial carcinoma stage I. *Int J Radiat Oncol Biol Phys* 1990; 18: 305-314.

14. Guy CL, Fields EC, Quinn BA et al. The vaginal cylinder: Misunderstood, misused, or trivial? An in-depth dosimetric and multiinstitutional outcome investigation. *Brachytherapy* 2019; 18: 763-770.

15. Bahng AY, Dagan A, Bruner DW et al. Determination of prognostic factors for vaginal mucosal toxicity associated with intravaginal high-dose rate brachytherapy in patients with endometrial cancer. *Int J Radiat Oncol Biol Phys* 2012; 82: 667-673.

16. Aguiler MDV, Rovirosa A, Ascaso C et al. Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction (α/β= 3Gy)) at 2 cm(3) of vagina. *J Contemp Brachytherapy* 2018; 10: 40-46.

17. Kloetzer KH, Günther R, Wendt T. The vaginal stump recurrence in endometrial carcinoma in relation to the target volume of postoperative HDR-afterloading brachytherapy. *Strahlenther Onkol* 1997; 173: 13-17.

18. Choo JJ, Scudiere J, Bitterman P et al. Vaginal lymphatic channel location and its implication for intracavitary brachytherapy radiation treatment. *Brachytherapy* 2005; 4: 236-240.

19. Townamchai K, Lee L, Viswanathan AN. A novel low dose fractionation regimen for adjuvant vaginal brachytherapy in early stage endometrioid endometrial cancer. *Gynecol Oncol* 2012; 127: 351-355.

20. Ma DJ, Michaletz-Lorenz M, Goddu SM et al. Magnitude of interfractional vaginal cuff movement: implications for external irradiation. *Int J Radiat Oncol Biol Phys* 2012; 82: 1439-1444.

21. Jhingran A, Salehpour M, Sam M et al. Vaginal motion and bladder and rectal volumes during pelvic intensity-modulated radiation therapy after hysterectomy. *Int J Radiat Oncol Biol Phys* 2012; 82: 256-262.

22. Ozdemir Y, Dolek Y, Onal C. Effects of vaginal cylinder position on dose distribution in patients with endometrial carcinoma in treatment of vaginal cuff brachytherapy. *J Contemp Brachytherapy* 2017; 9: 230-235.

23. Chino JP, Jones E, Berchuck A et al. The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. *Int J Radiat Oncol Biol Phys* 2012; 82: 1872-1879.

24. Lee CM, Szabo A, Shrieve DC et al. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. *JAMA* 2006; 295: 389-397.

25. Xiang M, Kidd EA. Survival benefit of radiation in high-risk, early-stage endometrioid carcinoma. *J Gynecol Oncol* 2020; 31: e39.

26. Hou XR, Yu L, Hu K et al. Outcomes of intermediate-risk to high-risk stage I endometrial cancer: 10-year clinical experiences of using in-house multi-channel applicators in a single center. *Chin Med J (Engl.)* 2019; 132: 1935-1941.

27. Zhang Y, Ascaso C, Herreros A et al. Postoperative endometrial carcinoma treated with external beam irradiation plus vaginal-cuff brachytherapy: Is there a dose relationship with G2 vaginal complications? *Rep Pract Oncol Radiother* 2020; 25: 227-232.

28. Rovirosa A, Herreros A, Camacho C et al. Comparative results of three short brachytherapy schedules as exclusive treatment in postoperative endometrial carcinoma. *Brachytherapy* 2017; 16: 1169-1174.

29. Sorbe B, Horvath G, Andersson H et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma – a prospective randomized study. *Int J Radiat Oncol Biol Phys* 2012; 82: 1249-1255.

30. Diavolitsis V, Rademaker A, Lurain J et al. Clinical outcomes in International Federation of Gynecology and Obstetrics stage IA endometrial cancer with myometrial invasion treated with or without postoperative vaginal brachytherapy. *Int J Radiat Oncol Biol Phys* 2012; 84: 415-419.

31. Alektiar KM, Venkatraman E, Chi DS et al. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. *Int J Radiat Oncol Biol Phys* 2005; 62: 111-117.

32. Horowitz NS, Peters WA 3rd, Smith MR et al. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. *Obstet Gynecol* 2002; 99: 235-240.

33. Petereit DG, Tannehill SP, Gosen EA et al. Outpatient vaginal cuff brachytherapy for endometrial cancer. *J Gynecol Cancer* 1999; 9: 456-462.

34. Eltabbakh GH, Piver MS, Hempling RE et al. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. *Int J Radiat Oncol Biol Phys* 1997; 38: 373-380.

35. Park HS, Ratner ES, Lucarelli L et al. Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma. *Brachytherapy* 2015; 14: 464-470.

36. Law E, Kelvin JF, Thom B et al. Prospective study of vaginal dilator use adherence and efficacy following radiotherapy. *Radiother Oncol* 2015; 116: 149-155.

37. Son CH, Law E, Oh JH et al. Dosimetric predictors of radiation-induced vaginal stenosis after pelvic radiation therapy for rectal and anal cancer. *Int J Radiat Oncol Biol Phys* 2015; 92: 548-554.

38. Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev 2014; 2014: CD007291-CD007291.

39. Bruner DW, Nolte SA, Shahin MS et al. Measurement of vaginal cuff brachytherapy in patients with endometrial carcinoma treated with or without postoperative vaginal brachytherapy. *Strahlenther Onkol* 1997; 9: 456-462.

40. Bruner DW, Lurain J, Keegan M et al. Vaginal motion and bladder and rectal volumes during pelvic intensity-modulated radiation therapy after hysterectomy. *Int J Radiat Oncol Biol Phys* 2012; 82: 256-262.

41. Ozdemir Y, Dolek Y, Onal C. Effects of vaginal cylinder position on dose distribution in patients with endometrial carcinoma in treatment of vaginal cuff brachytherapy. *J Contemp Brachytherapy* 2017; 9: 230-235.

42. Chino JP, Jones E, Berchuck A et al. The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. *Int J Radiat Oncol Biol Phys* 2012; 82: 1872-1879.

43. Lee CM, Szabo A, Shrieve DC et al. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. *JAMA* 2006; 295: 389-397.

44. Xiang M, Kidd EA. Survival benefit of radiation in high-risk, early-stage endometrioid carcinoma. *J Gynecol Oncol* 2020; 31: e39.

45. Hou XR, Yu L, Hu K et al. Outcomes of intermediate-risk to high-risk stage I endometrial cancer: 10-year clinical experiences of using in-house multi-channel applicators in a single center. *Chin Med J (Engl.)* 2019; 132: 1935-1941.